Literature DB >> 28218801

Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States.

Zhiyuan Zheng1,2, Xuesong Han1, Gery P Guy3, Amy J Davidoff4, Chunyu Li3, Matthew P Banegas5, Donatus U Ekwueme3, K Robin Yabroff6, Ahmedin Jemal1.   

Abstract

BACKGROUND: There is limited evidence from nationally representative samples about changes in prescription drug use for financial reasons among cancer survivors in the United States.
METHODS: The 2011 to 2014 National Health Interview Survey was used to identify adults who reported ever having been told they had cancer (cancer survivors; n = 8931) and individuals without a cancer history (n = 126,287). Measures of changes in prescription drug use for financial reasons included: 1) skipping medication doses, 2) taking less medicine, 3) delaying filling a prescription, 4) asking a doctor for lower cost medication, 5) buying prescription drugs from another country, and 6) using alternative therapies. Multivariable logistic regression analyses were controlled for demographic characteristics, number of comorbid conditions, interactions between cancer history and number of comorbid conditions, and health insurance coverage. Main analyses were stratified by age (nonelderly, ages 18-64 years; elderly, ages ≥65 years) and time since diagnosis (recently diagnosed, <2 years; previously diagnosed, ≥2 years).
RESULTS: Among nonelderly individuals, both recently diagnosed (31.6%) and previously diagnosed (27.9%) cancer survivors were more likely to report any change in prescription drug use for financial reasons than those without a cancer history (21.4%), with the excess percentage changes for individual measures ranging from 3.5% to 9.9% among previously diagnosed survivors and from 2.6% to 2.7% among recently diagnosed survivors (P < .01). Elderly cancer survivors and those without a cancer history had comparable rates of changes in prescription drug use for financial reasons.
CONCLUSIONS: Nonelderly cancer survivors are particularly vulnerable to changes in prescription drug use for financial reasons, suggesting that targeted efforts are needed. Cancer 2017;123:1453-1463.
© 2016 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  cancer survivors; comorbid conditions; financial burden; high-deductible plan; prescription drugs

Mesh:

Substances:

Year:  2017        PMID: 28218801      PMCID: PMC6080209          DOI: 10.1002/cncr.30560

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  58 in total

1.  Gender differences in cost-related medication non-adherence among cancer survivors.

Authors:  Minjee Lee; M Mahmud Khan
Journal:  J Cancer Surviv       Date:  2015-09-09       Impact factor: 4.442

2.  Benefit design and specialty drug use.

Authors:  Dana P Goldman; Geoffrey F Joyce; Grant Lawless; William H Crown; Vincent Willey
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

3.  Full disclosure--out-of-pocket costs as side effects.

Authors:  Peter A Ubel; Amy P Abernethy; S Yousuf Zafar
Journal:  N Engl J Med       Date:  2013-10-17       Impact factor: 91.245

4.  Regional variation in spending and survival for older adults with advanced cancer.

Authors:  Gabriel A Brooks; Ling Li; Dhruv B Sharma; Jane C Weeks; Michael J Hassett; K Robin Yabroff; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2013-03-12       Impact factor: 13.506

5.  Changes in Medication Management After a Diagnosis of Cancer Among Medicare Beneficiaries With Diabetes.

Authors:  Bruce C Stuart; Amy J Davidoff; Mujde Z Erten
Journal:  J Oncol Pract       Date:  2015-06-23       Impact factor: 3.840

6.  Impact of medication adherence on hospitalization risk and healthcare cost.

Authors:  Michael C Sokol; Kimberly A McGuigan; Robert R Verbrugge; Robert S Epstein
Journal:  Med Care       Date:  2005-06       Impact factor: 2.983

7.  Impact of age at diagnosis on prostate cancer treatment and survival.

Authors:  Seth K Bechis; Peter R Carroll; Matthew R Cooperberg
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

8.  Patient preferences for oral versus intravenous palliative chemotherapy.

Authors:  G Liu; E Franssen; M I Fitch; E Warner
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

9.  Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study.

Authors:  S Yousuf Zafar; Rebecca B McNeil; Catherine M Thomas; Christopher S Lathan; John Z Ayanian; Dawn Provenzale
Journal:  J Oncol Pract       Date:  2014-12-16       Impact factor: 3.840

10.  The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.

Authors:  S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy
Journal:  Oncologist       Date:  2013-02-26
View more
  21 in total

1.  Evaluation of a Novel Financial Navigator Pilot to Address Patient Concerns about Medical Care Costs.

Authors:  Matthew P Banegas; John F Dickerson; Nicole L Friedman; David Mosen; Althea X Ender; T Ruth Chang; Tracy A Runge; Mark C Hornbrook
Journal:  Perm J       Date:  2019

Review 2.  Economic Burden Associated with Cancer Caregiving.

Authors:  Cathy J Bradley
Journal:  Semin Oncol Nurs       Date:  2019-06-20       Impact factor: 2.315

3.  Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.

Authors:  Christine Leopold; Anita K Wagner; Fang Zhang; Christine Y Lu; Craig C Earle; Larissa Nekhlyudov; Dennis Ross-Degnan; J Frank Wharam
Journal:  Breast Cancer Res Treat       Date:  2018-06-01       Impact factor: 4.872

4.  The social and economic toll of cancer survivorship: a complex web of financial sacrifice.

Authors:  Matthew P Banegas; Jennifer L Schneider; Alison J Firemark; John F Dickerson; Erin E Kent; Janet S de Moor; Katherine S Virgo; Gery P Guy; Donatus U Ekwueme; Zhiyuan Zheng; Alexandra M Varga; Lisa A Waiwaiole; Stephanie M Nutt; Aditi Narayan; K Robin Yabroff
Journal:  J Cancer Surviv       Date:  2019-05-23       Impact factor: 4.442

5.  Patterns in Health Care Access and Affordability Among Cancer Survivors During Implementation of the Affordable Care Act.

Authors:  Ryan D Nipp; Amy M Shui; Giselle K Perez; Anne C Kirchhoff; Jeffrey M Peppercorn; Beverly Moy; Karen Kuhlthau; Elyse R Park
Journal:  JAMA Oncol       Date:  2018-06-01       Impact factor: 31.777

6.  Race, financial hardship, and limiting care due to cost in a diverse cohort of cancer survivors.

Authors:  Theresa A Hastert; Matthew P Banegas; Lauren M Hamel; Amanda R Reed; Tara Baird; Jennifer L Beebe-Dimmer; Ann G Schwartz
Journal:  J Cancer Surviv       Date:  2019-05-29       Impact factor: 4.442

Review 7.  Financial toxicity and implications for cancer care in the era of molecular and immune therapies.

Authors:  George Tran; S Yousuf Zafar
Journal:  Ann Transl Med       Date:  2018-05

8.  Effect of patient age on glioblastoma perioperative treatment costs: a value driven outcome database analysis.

Authors:  Brandon A Sherrod; Nicholas T Gamboa; Christopher Wilkerson; Herschel Wilde; Mohammed A Azab; Michael Karsy; Randy L Jensen; Sarah T Menacho
Journal:  J Neurooncol       Date:  2019-05-04       Impact factor: 4.130

9.  Exploring barriers to the receipt of necessary medical care among cancer survivors under age 65 years.

Authors:  Matthew P Banegas; John F Dickerson; Erin E Kent; Janet S de Moor; Katherine S Virgo; Gery P Guy; Donatus U Ekwueme; Zhiyuan Zheng; Stephanie Nutt; Loyce Pace; Alexandra Varga; Lisa Waiwaiole; Jennifer Schneider; K Robin Yabroff
Journal:  J Cancer Surviv       Date:  2017-08-29       Impact factor: 4.442

10.  Adherence to Multiple Treatment Recommendations in Adolescents and Young Adults with Cancer: A Mixed Methods, Multi-Informant Investigation.

Authors:  Alexandra M Psihogios; Lisa A Schwartz; Kylie B Ewing; Bryn Czerniecki; Leslie S Kersun; Ahna L H Pai; Janet A Deatrick; Lamia P Barakat
Journal:  J Adolesc Young Adult Oncol       Date:  2020-05-11       Impact factor: 2.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.